Belzutifan, marketed as Welireg, is an innovative targeted therapy that has transformed treatment options for certain patients with von Hippel-Lindau (VHL) disease–associated tumors and advanced renal cell carcinoma (RCC).

As a first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, Belzutifan addresses a critical pathway involved in tumor growth and survival. However, despite its clinical value, access to new therapies can be delayed in some countries due to regulatory timelines, reimbursement processes or local availability challenges.

In patients with VHL disease, the lack of a functional VHL protein leads to an abnormal accumulation of HIF-2α, which then triggers the growth of tumors in various organs, including the kidneys, brain and pancreas.

The efficacy of Welireg, primarily established through clinical trials, showed remarkable results for VHL-associated tumors:

  • Renal Cell Carcinoma (RCC): Achieved a response rate of 49%.
  • Pancreatic Neuroendocrine Tumors (pNETs): 83% minimum objective response rate in various trials.
  • CNS Hemangioblastomas: response rate of 63%.

As Welireg can stabilize or even shrink these tumors, it has the potential to significantly delay or reduce the need for surgical interventions, which often carry risks like diabetes or loss of organ function.

The Role of Named Patient Access (NPA)

While there exist formal regulatory approvals, Named Patient Access (NPA) is a common global pathway for patients to receive medications before they are commercially available in their specific country.

Named Patient Access (NPA) programs help bridge this gap by enabling physicians to request treatment for eligible patients before commercial availability or when a medicine is not yet registered in their country. Through these pathways, patients with serious or life-threatening conditions may gain access to potentially beneficial therapies under the supervision of their treating physician.

Although innovative medicines may receive approval in major markets such as the United States or Europe, patients in other regions often face delays before local regulatory approvals are completed. These delays can be particularly significant for individuals living with rare diseases or advanced cancers, where treatment options may be limited.

For patients whose physicians determine that Belzutifan may be clinically appropriate, waiting for local commercialization may not be feasible. This is where Named Patient Access programs can play an important role.

What is Named Patient Access?

Named Patient Access is a legal and regulated mechanism that allows physicians to request a medicine for an individual patient when:

  1. The medicine is not commercially available in the patient’s country.
  2. There is a significant unmet medical need.
  3. The treating physician believes the medicine may provide clinical benefit.
  4. Access is requested on a patient-specific basis and complies with local regulations.

Unlike clinical trials, Named Patient Access programs are not designed to generate research data. Instead, they focus on enabling treatment access for patients with serious conditions when conventional options are unavailable, unsuitable or exhausted.

How Belzutifan reaches patients through Named Patient Access

  1. Physician identifies a clinical need:
    The process begins when an oncologist or specialist determines that a patient may benefit from Belzutifan based on their diagnosis, treatment history, and clinical status. For example, a patient with advanced RCC who has already received PD-1/PD-L1 therapy and VEGF-targeted treatment may be considered a potential candidate.
  2. Eligibility assessment:
    The treating physician reviews whether the patient meets the relevant medical criteria and whether access through a Named Patient pathway is permitted under local regulations. Clinical factors may include disease stage, previous treatments, overall health status, potential risks and benefits and availability of alternative therapies
  3. Submission of a named patient request:

    The physician submits the necessary documentation to obtain access. Requirements vary by country but often include the following:

    • Medical justification
    • Patient clinical history
    • Confirmation of unmet medical need
    • Regulatory and import documentation where applicable
  4. Regulatory and compliance review:
    Depending on local laws, the request may undergo review by health authorities, ethics committees, or authorized access providers to ensure compliance with applicable regulations.
  5. Medicine procurement and supply:
    Once approved, Belzutifan is sourced and supplied through authorized channels. The medicine is then delivered to the treating institution or healthcare provider for patient use.
  6. Ongoing physician monitoring:
    Treatment remains under the direct supervision of the prescribing physician. Patients receiving Belzutifan require regular monitoring because the therapy can cause clinically significant adverse events, including anemia and hypoxia. Monitoring of hemoglobin levels and oxygen saturation is recommended before and during treatment.

Why NPA matters?

Named Patient Access programs offer several important benefits:

  1. Patients may receive potentially beneficial therapies before local commercial launch or reimbursement decisions are finalized.
  2. Patients with rare conditions such as VHL disease often face limited treatment options. Named Patient Access can provide an avenue to obtain therapies that may otherwise be unavailable.
  3. When patients relocate or when local supply is unavailable, Named Patient programs may help maintain treatment continuity under physician supervision.
  4. Access decisions are made on a patient-by-patient basis, allowing physicians to evaluate whether the potential benefits outweigh the risks for each individual.

Important Safety Considerations

As with any prescription medicine, Belzutifan should only be used under the guidance of a qualified healthcare professional.

Important safety considerations include:

  • Risk of severe anemia that may require monitoring and, in some cases, blood transfusion.
  • Hypoxia risk, which may require dose interruption, oxygen supplementation or treatment discontinuation.
  • Embryo-fetal toxicity; effective non-hormonal contraception is recommended during treatment and for one week after the last dose.

Treatment decisions should always be based on local prescribing information, physician judgment and patient-specific clinical considerations.

Belzutifan (or Welireg) represents a significant advancement in targeted oncology therapy, offering a novel treatment approach for eligible patients with VHL-associated tumors and advanced RCC. While regulatory and market access timelines can vary globally, Named Patient Access programs provide a valuable mechanism for helping eligible patients obtain Belzutifan treatment when local availability is limited.

By enabling physician-led access to innovative therapies, Named Patient Access programs can help address urgent unmet medical needs and ensure that patients have the opportunity to receive appropriate treatment while broader commercial access pathways continue to develop.